Pre-made Pexelizumab benchmark antibody (scFv, anti-C5/CO5 therapeutic antibody, Anti-CPAMD4/ECLZB Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Pexelizumab benchmark antibody (scFv, anti-C5/CO5 therapeutic antibody, Anti-CPAMD4/ECLZB Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pexelizumab is a drug designed to reduce side effects of coronary artery bypass grafting[1] and angioplasty,[2][3] among other types of cardiac surgery. It is a single chain variable fragment of a monoclonal antibody targeted against component 5 of the complement system.[4]
| Products Name (INN Index) | Pre-Made Pexelizumab Biosimilar, Scfv, Anti-C5/CO5 Antibody: Anti-CPAMD4/ECLZB therapeutic antibody |
|---|---|
| INN Name | pexelizumab |
| Target | C5 |
| Format | scFv |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | scFv – nd – nd |
| VD LC | scFv – nd – nd |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Alexion Pharmaceuticals Inc. (New Haven CT USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | C5 |
| Package |
